♟️ Friday 29 August 2025 Fri, 29 Aug 2025

MedAdvisor reported a 36% revenue drop in FY25, driven by US health program setbacks, and sold its ANZ business to focus on restructuring its US operations.

Alterity Therapeutics reported a reduced net loss of A$12.15 million for FY2025, buoyed by positive Phase 2 clinical trial results for its lead drug ATH434 in Multiple System Atrophy and a successful A$40 million capital raising.

4DMedical reports a robust 56% revenue increase in FY2025, driven by SaaS expansion and strategic partnerships, while advancing FDA clearance for its innovative CT – VQ™ lung imaging software.

betr Entertainment has lodged a formal application with the Takeovers Panel, contesting PointsBet’s board decision to accelerate vesting of performance rights amid competing takeover bids, a move that significantly boosted MIXI’s voting power.

BCAL Diagnostics has launched its first commercial breast cancer diagnostic test, BREASTESTplus™, in Australia, marking a key milestone despite a $7.24 million loss for FY2025. The company is also advancing its US operations with a new subsidiary and clinical trials underway.

Bubs Australia Limited reports a striking turnaround in FY25 with revenue up 29% to $102.5 million and net profit soaring 124% to $5.17 million, driven by strong US and China growth. The company awaits permanent FDA approval, a pivotal factor for its future trajectory.

DorsaVi Limited reported a 13.9% revenue decline and a 21.7% rise in net loss for FY25, while securing over $3 million in capital to fuel new technology ventures.

Magnum Mining & Exploration has initiated leach testing on high-grade samples from its Palmares Rare Earth Element Project in Brazil, aiming to validate recovery rates ahead of planned drilling. Results expected by September will guide the next phase of exploration across its extensive REE portfolio.

Gale Pacific’s FY25 results reveal resilience amid US market challenges, with growth in Australia and the Middle East offsetting tariff impacts and prompting a major US operating restructure.

GALE Pacific reported a slight revenue dip and a net loss in FY25, driven by US market challenges including tariffs and weak consumer demand. The company is now overhauling its US operations and diversifying manufacturing to restore profitability.

Atomo Diagnostics reported a 27% reduction in net loss to AUD 4.97 million for FY25, alongside a 7% revenue dip to AUD 3.79 million, driven by stronger margins and cost controls. The company also secured a significant US distribution contract through partner Lumos Diagnostics, positioning it for growth.

Immutep Limited reported a widened loss of A$61.4 million for FY2025, driven by increased R&D and clinical trial expenses, while progressing its lead immunotherapy candidate into a pivotal Phase III lung cancer trial. The company maintains a robust cash position supporting operations through 2026.

FlexiRoam Limited reported an 8.6% revenue decline for FY25 but achieved a remarkable turnaround in the second half, posting positive EBITDA and net profit after a CEO-led operational reset.

3P Learning reported a 30% rise in underlying EBITDA to $15.5 million for FY25, alongside a return to statutory profitability and a key acquisition to strengthen its literacy offerings.

Pure Foods Tasmania has executed a decisive operational and financial turnaround, cutting costs and strengthening its balance sheet, while targeting breakeven by mid-2026 with ambitious growth plans.

Mayne Pharma Group Limited reported a robust FY25 with a 5% revenue increase to A$408.1 million and a 105% surge in underlying EBITDA, driven by strong growth in Women’s Health and strategic acquisitions in Dermatology.

Mayne Pharma reported a robust 5% revenue increase to $408.1 million and more than doubled its underlying EBITDA to $47 million in FY25, driven by strong Women’s Health sales and strategic acquisitions in Dermatology.

PointsBet reports a 6% revenue increase and returns to normalised EBITDA profitability in FY25, while the board unanimously backs MIXI Australia’s all-cash $1.25 per share takeover offer, urging shareholders to reject a rival hostile bid.

Aerometrex reported a slight dip in overall revenue for FY25 but achieved record growth in its MetroMap subscription business, driving a 19.8% rise in EBITDA. Strategic shifts and new leadership position the company for a leaner, more profitable future.

Harvey Norman Holdings Limited reported robust FY25 results with strong sales growth, a significant profit increase, and a major boost from property revaluations. The company’s integrated retail, franchise, and property model continues to underpin its expansion and resilience.

Harvey Norman Holdings reported a robust 39% jump in profit before tax for FY25, driven by strong franchise sales, a booming property portfolio, and strategic international expansion.

Harvey Norman Holdings Limited reported strong FY25 financial results, driven by growth in franchisee sales, property portfolio appreciation, and digital investments. The company’s integrated retail, franchise, property, and digital system across multiple countries underpins its sustained shareholder returns.

Dubber Corporation Limited reported a 9% increase in revenue to $42.19 million for FY25, alongside a significant reduction in net loss. However, challenges remain with a major contract non-renewal and ongoing efforts to recover $26.6 million in misused funds.

Murray Cod Australia Limited has reported a remarkable turnaround with a $8.56 million profit for FY25, driven by expanded production capacity and growing export markets. The company’s strategic focus on domestic strength and sustainable growth underpins its rising global profile.